Early Trials Suggest New Path for CAR T-Cell Therapy in Solid Tumors

Brittany Lovely
Published: Friday, May 10, 2019
Prasad S. Adusumilli, MD
Prasad S. Adusumilli, MD
Two novel chimeric antigen receptor (CAR) T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.

Table 1. Mesothelin-Targeted CAR T Cells in Pleural Malignancies

Table 1. Mesothelin-Targeted CAR T Cells in Pleural Malignancies

Table 2. HER2 CAR T Cells in Sarcomas

Table 2. HER2 CAR T Cells in Sarcomas The participants in the study included patients with malignant pleural mesothelioma, lung cancer, and breast cancers; 40% had received ≥3 lines of prior therapy.3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x